IPO registrations (S-1, F-1) · Registrants
AbCellera Biologics Inc.
- SEC CIK
- 1703057 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2020-11-20, last 2021-06-10; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2020-12-14; declared effective 2020-12-10
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- A1
- Business address
- 150 W 4TH AVENUE, Vancouver, A1 V5Y 1G6
- Ticker
- ABCL (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- AbCellera Biologics Inc. on the corporate pages
Offering terms
- Proposed price range
- $17.00–$18.00 per share (S-1/A filed 2020-12-10)
- Final price
- $20.00 per share, above the range (424B4 filed 2020-12-14, an initial public offering)
- Shares sold
- 24,150,000
- Gross proceeds
- $483,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ABCL
- Lead underwriters
- Credit Suisse; Stifel (4,347,000 shares); Leerink Partners (4,347,000 shares); BMO Capital Markets (3,381,000 shares); Berenberg Capital Markets LLC (4,347,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: AbCellera Biologics Inc. EXACT (CIK (EXACT))
- SEC filer: AbCellera Biologics Inc. EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-11-20 | S-1 | S-1 (registration) | AbCellera Biologics Inc. | 0001193125-20-299507 ↗ |
| 2020-11-25 | S-1/A | S-1/A (amendment) | AbCellera Biologics Inc. | 0001193125-20-302988 ↗ |
| 2020-12-07 | S-1/A | S-1/A (amendment) | AbCellera Biologics Inc. | 0001193125-20-311091 ↗ |
| 2020-12-10 | S-1/A | S-1/A (amendment) | AbCellera Biologics Inc. | 0001193125-20-314458 ↗ |
| 2020-12-10 | S-1MEF | S-1MEF (added securities) | AbCellera Biologics Inc. | 0001193125-20-315173 ↗ |
| 2020-12-10 | EFFECT | EFFECT (declared effective) | AbCellera Biologics Inc. | 9999999995-20-003483 ↗ |
| 2020-12-14 | 424B4 | 424B4 (final prospectus) | AbCellera Biologics Inc. | 0001193125-20-316986 ↗ |
| 2021-06-10 | S-1 | S-1 (registration) | AbCellera Biologics Inc. | 0001193125-21-187930 ↗ |
| 2021-06-21 | EFFECT | EFFECT (declared effective) | AbCellera Biologics Inc. | 9999999995-21-002431 ↗ |
| 2022-08-11 | EFFECT | EFFECT (declared effective) | AbCellera Biologics Inc. | 9999999995-22-002331 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-10 | S-1/A | registration statement | $17.00–$18.00 | 23,000,000 | - | Nasdaq ABCL | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2020-12-14 | 424B4 | final prospectus | $20.00 | 24,150,000 | $483,000,000 | Nasdaq ABCL | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bogue Zachary | TenPercentOwner | 4 | 2020–2021 | ||
| Booth Andrew | Officer | Chief Financial Officer | 17 | 2020–2026 | |
| DCVC Bio GP, LLC | TenPercentOwner | 4 | 2020–2021 | ||
| DCVC Bio, L.P. | TenPercentOwner | 4 | 2020–2021 | ||
| HAMER JOHN | Director; Director,TenPercentOwner | 4 | 2020–2021 | ||
| Hansen Carl L. G. | Director,Officer,TenPercentOwner | Chief Executive Officer | 21 | 2020–2026 | |
| Hayden Michael R | Director | 14 | 2020–2026 | ||
| Lecault Veronique | Director,Officer | Chief Operating Officer; Chief Technology Officer | 18 | 2020–2026 | |
| Montalbano John S. | Director | 16 | 2020–2026 | ||
| Ocko Matthew | TenPercentOwner | 4 | 2020–2021 | ||
| Stead Kiersten | TenPercentOwner | 4 | 2020–2021 | ||
| Stimart Tryn | Officer | Chief Legal Officer | 9 | 2020–2026 | |
| Thermopylae Holdings Ltd. | TenPercentOwner | 19 | 2020–2026 | ||
| THIEL PETER | Director | 2 | 2020 | ||
| ZNM Capital Management, LLC | TenPercentOwner | 4 | 2020–2021 | ||
| JNK Capital Management, LLC | TenPercentOwner | 3 | 2020–2021 | ||
| Falconer Ester | Officer | Chief Technology Officer | 5 | 2021 | |
| Lo Andrew | Director | 6 | 2021–2025 | ||
| Quake Stephen | Director | 3 | 2025–2026 | ||
| Sandor Victor | Director | 2 | 2026 | ||
| Seely Lynn | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-05-27 | AbCellera Biologics Inc. | Biotechnology | $74,500,235 | $74,500,235 | 14 | 1 |
| 2018-08-10 | AbCellera Biologics Inc. | Biotechnology | $7,702,383 | $7,702,383 | 1 | 1 |
| 2018-03-19 | AbCellera Biologics Inc. | Biotechnology | $484,475 | $50,000 | 1 | 1 |
| 2017-04-06 | AbCellera Biologics Inc. | Biotechnology | $863,329 | $817,878 | 24 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | AbCellera Biologics Inc. | Form D private offerings | CIK (EXACT) | |
| SEC filer | AbCellera Biologics Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, A1 first:
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
- BriaCell Therapeutics Corp. A1
- Old API Wind-down Ltd. A1
- BODY & MIND INC. A1
- XORTX Therapeutics Inc. A1
In other datasets, the same topic (Health) in A1:
- Form D issuer: 1219014 B.C. Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health